These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25325532)

  • 21. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
    Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Rossini R; Musumeci G; Capodanno D; Lettieri C; Limbruno U; Tarantini G; Russo N; Calabria P; Romano M; Inashvili A; Sirbu V; Guagliumi G; Valsecchi O; Senni M; Gavazzi A; Angiolillo DJ
    Thromb Haemost; 2015 Feb; 113(2):272-82. PubMed ID: 25274620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
    Feres F; Costa RA; Bhatt DL; Leon MB; Botelho RV; King SB; de Paula JE; Mangione JA; Salvadori D; Gusmão MO; Castello H; Nicolela E; Perin MA; Devito FS; Marin-Neto JA; Abizaid A
    Am Heart J; 2012 Dec; 164(6):810-6.e3. PubMed ID: 23194480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.
    Kubica A; Kasprzak M; Obońska K; Fabiszak T; Laskowska E; Navarese EP; Koziński M; Sztuba B; Świątkiewicz I; Grześk G; Kubica J
    Pharmacology; 2015; 95(1-2):50-8. PubMed ID: 25592409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adherence to antiplatelet therapy in patients with coronary artery disease].
    Legrand D; Legrand V
    Rev Med Liege; 2010; 65(5-6):304-10. PubMed ID: 20684411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
    Harjai KJ; Shenoy C; Orshaw P; Boura J
    Heart; 2009 Oct; 95(19):1579-86. PubMed ID: 19549619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
    Brener SJ; Steinhubl SR; Berger PB; Brennan DM; Topol EJ;
    J Invasive Cardiol; 2007 Jul; 19(7):287-90. PubMed ID: 17620671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
    Varenhorst C; Jensevik K; Jernberg T; Sundström A; Hasvold P; Held C; Lagerqvist B; James S
    Eur Heart J; 2014 Apr; 35(15):969-78. PubMed ID: 24122961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clopidogrel: the data, the experience, and the controversies.
    Sadanandan S; Singh IM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    Camenzind E; Boersma E; Wijns W; Mauri L; Rademaker-Havinga T; Ordoubadi FF; Suttorp MJ; Al Kurdi M; Steg PG;
    Eur Heart J; 2014 Aug; 35(29):1932-48. PubMed ID: 24627416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
    Lip GY; Karpha M
    Chest; 2006 Dec; 130(6):1823-7. PubMed ID: 17167003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Chen KY; Rha SW; Li YJ; Poddar KL; Jin Z; Minami Y; Wang L; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
    Circulation; 2009 Jun; 119(25):3207-14. PubMed ID: 19528339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Percutaneous Coronary Intervention Performed With or Without Preprocedural Dual Antiplatelet Therapy.
    Ikegami Y; Kohsaka S; Miyata H; Ueda I; Fuse J; Sakamoto M; Shiraishi Y; Numasawa Y; Negishi K; Nakamura I; Maekawa Y; Momiyama Y; Fukuda K
    Circ J; 2015; 79(12):2598-607. PubMed ID: 26447105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of cilostazol in patients with acute coronary syndrome after percutaneous coronary intervention.
    Hu T; Ma H; Li H; Ren J
    Am J Ther; 2013; 20(2):151-3. PubMed ID: 22975664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to Antiplatelet Therapy after Coronary Intervention among Patients with Myocardial Infarction Attending Vietnam National Heart Institute.
    Luu NM; Dinh AT; Nguyen TTH; Nguyen VH
    Biomed Res Int; 2019; 2019():6585040. PubMed ID: 31179331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting.
    López J; Morales C; Avanzas P; Callejo F; Hernández-Vaquero D; Llosa JC
    J Card Surg; 2013 Jul; 28(4):366-72. PubMed ID: 23879339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.